+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Prevention of Kupffer cell-induced oxidant injury in rat liver by atrial natriuretic peptide



Prevention of Kupffer cell-induced oxidant injury in rat liver by atrial natriuretic peptide



American Journal of Physiology 276(5 Pt 1): G1137-G1144



The generation of reactive oxygen species (ROS) by activated Kupffer cells contributes to liver injury following liver preservation, shock, or endotoxemia. Pharmacological interventions to protect liver cells against this inflammatory response of Kupffer cells have not yet been established. Atrial natriuretic peptide (ANP) protects the liver against ischemia-reperfusion injury, suggesting a possible modulation of Kupffer cell-mediated cytotoxicity. Therefore, we investigated the mechanism of cytoprotection by ANP during Kupffer cell activation in perfused rat livers of male Sprague-Dawley rats. Activation of Kupffer cells by zymosan (150 mg/ml) resulted in considerable cell damage, as assessed by the sinusoidal release of lactate dehydrogenase and purine nucleoside phosphorylase. Cell damage was almost completely prevented by superoxide dismutase (50 U/ml) and catalase (150 U/ml), indicating ROS-related liver injury. ANP (200 nM) reduced Kupffer cell-induced injury via the guanylyl cyclase-coupled A receptor (GCA receptor) and cGMP: mRNA expression of the GCA receptor was found in hepatocytes, endothelial cells, and Kupffer cells, and the cGMP analog 8-bromo-cGMP (8-BrcGMP; 50 mM) was as potent as ANP in protecting from zymosan-induced cell damage. ANP and 8-BrcGMP significantly attenuated the prolonged increase of hepatic vascular resistance when Kupffer cell activation occurred. Furthermore, both compounds reduced oxidative cell damage following infusion of H2O2 (500 mM). In contrast, superoxide anion formation of isolated Kupffer cells was not affected by ANP and only moderately reduced by 8-BrcGMP. In conclusion, ANP protects the liver against Kupffer cell-related oxidant stress. This hormonal protection is mediated via the GCA receptor and cGMP, suggesting that the cGMP receptor plays a critical role in controlling oxidative cell damage. Thus ANP signaling should be considered as a new pharmacological target for protecting liver cells against the inflammatory response of activated Kupffer cells without eliminating the vital host defense function of these cells. Reprinted by permission of the publisher.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 009946639

Download citation: RISBibTeXText

PMID: 10330004


Related references

Prevention of Kupffer cell-induced oxidant injury in rat liver by atrial natriuretic peptide. American Journal of Physiology. Gastrointestinal and Liver Physiology 276(5): G1137-G1144, 2018

Prevention of Kupffer cell-induced injury in rat liver by atrial natriuretic peptide A novel endogenous defense mechanism against oxidant injury. Hepatology 28(4 Part 2): 323A, 1998

Reduction of Kupffer cell-induced oxidant injury of the rat liver by atrial natriuretic peptide and cyclo-GMP receptor proteins. Journal of Hepatology 28(Suppl. 1): 47, 1998

C-GMP-MMediated protection against kupffer cell -induced liver injury by the atrial natriuretic peptide. Journal of Hepatology 23(Suppl. 1): 159, 1995

Protection against Kupffer cell mediated liver injury by the atrial natriuretic peptide. Hepatology 20(4 Part 2): 184A, 1994

Prevention of oxidative liver injury by atrial natriuretic peptide. Hepatology 24(4 Part 2): 237A, 1996

Prevention of ischemia/reperfusion injury in the rat liver by atrial natriuretic peptide. Gastroenterology 106(1): 143-151, 1994

Neutrophil and Kupffer cell-induced oxidant stress and ischemia-reperfusion injury in rat liver. American Journal of Physiology 260(3 Pt 1): G355-G362, 1991

N-terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma: investigation of plasma levels and molecular circulating form(s) using radioimmunoassays for pro-atrial natriuretic peptide (31-67), pro-atrial natriuretic peptide (1-30) and atrial natriuretic peptide (99-126). Clinical Science 87(3): 311-317, 1994

N-Terminal atrial natriuretic peptide and atrial natriuretic peptide in human plasma Investigation of plasma levels and molecular circulating form using radioimmunoassays for pro-atrial natriuretic peptide , pro-atrial natriuretic peptide and atrial natriuretic peptide. Clinical Science 87(3): 311-317, 1994

The atrial natriuretic peptide as a regulator of Kupffer cell functions. Shock 17(5): 365-371, 2002

Modulation of Kupffer cell function by atrial natriuretic peptide. Hepatology 22(4 Part 2): 308A, 1995

The Atrial Natriuretic Peptide as a Regular of Kupffer Cell Functions. Shock 17(5): 365-371, 2002

Prevention of Kupffer cell-induced injury in rat liver by glutathione. Hepatology 30(4 Part 2): 226A, 1999

Atrial natriuretic peptide attenuates oxidant induced lung edema. Clinical Research 37(1): 24A, 1989